Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selumetinib vs Temozolomide in Advanced Melanoma
NCT00338130Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2006
- Primary completion
- Sep 2007
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 2, randomised, open-label trial of selumetinib in melanoma (2 arms), sponsored by AstraZeneca. Primary endpoints: Progression-Free Survival at 6 months, Time to Death at 6 months and 2 more. Started Jul 2006; status: completed.
02
Drugs
selumetinib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00338130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00338130.